Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

BACKGROUND: Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain. AIM AND METHODS: We therefore evaluate the effects of anaglipt...

Descripción completa

Detalles Bibliográficos
Autores principales: Chihara, Atsuko, Tanaka, Atsushi, Morimoto, Takeshi, Sakuma, Mio, Shimabukuro, Michio, Nomiyama, Takashi, Arasaki, Osamu, Ueda, Shinichiro, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858725/
https://www.ncbi.nlm.nih.gov/pubmed/31733647
http://dx.doi.org/10.1186/s12933-019-0965-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858725/
https://www.ncbi.nlm.nih.gov/pubmed/31733647
http://dx.doi.org/10.1186/s12933-019-0965-3

Ejemplares similares